Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18002126 | 0.88 | KDM4E (0.51) | ALDH1A1KDM4ESMN1; SMN2MAPTATM | |
| SCHEMBL17894524 | 0.85 | MAPT (0.56) | ALDH1A1KDM4ESMN1; SMN2MAPTATM | |
| SCHEMBL28471906 | 0.84 | HDAC3 (0.50) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL28469757 | 0.83 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2MAPTCA12CA1 | |
| SCHEMBL1244152 | 0.81 | ALDH1A1 (0.55) | ALDH1A1KDM4ESMN1; SMN2MAPTATM | |
| SCHEMBL18002488 | 0.81 | ALDH1A1 (0.44) | ALDH1A1KDM4ESMN1; SMN2MAPTP2RX7 | |
| SCHEMBL28469213 | 0.80 | EPHX2 (0.48) | ALDH1A1MAPTCHRM5 | |
| SCHEMBL25753482 | 0.80 | ALDH1A1 (0.48) | ALDH1A1KDM4ESMN1; SMN2ATMHTT | |
| SCHEMBL18002201 | 0.80 | ALDH1A1 (0.46) | ALDH1A1KDM4ESMN1; SMN2MAPTATM | |
| SCHEMBL31622840 | 0.80 | ALDH1A1 (0.46) | ALDH1A1KDM4ESMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240775-A2 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS | Swansea University (GB) | 2017-11-08 | — | — | EP | claimed |
| WO-2016108045-A2 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS | SWANSEA UNIVERSITY (GB) | 2016-07-07 | — | — | WO | claimed |
| US-20170342025-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS | THE UNIVERSITY OF BATH (GB) | 2017-11-30 | — | — | US | disclosed |
| EP-3240775-A2 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS | Swansea University (GB) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016108045-A2 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS | SWANSEA UNIVERSITY (GB) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342025-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS | ZYX, MPO, CFB | ALDH1A1 1734/4885KDM4E 3336/4885SMN1; SMN2 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.